#LCSM Chat Topic for 12/4 8PM ET: “CMS lung cancer screening rules: overboard, or on the mark?”
The topic for #LCSM Chat on Thursday, December 4, 2014 at 8PM ET will be, “CMS lung cancer screening rules: overboard, or on the mark?” Our moderator Janet Freeman-Daily (@JFreemanDaily) will lead our discussion using the topics below. You can learn more about #LCSM Chat and how to join it here. T1: Do you agree with patient characteristics defined in CMS proposed lung cancer screening coverage? T2: Do you agree there is potential harm in lung cancer screening at centers that don’t have counseling or extensive experience? T3: Will CMS limitations channel… Read More
#LCSM Chat Topic 9/25: Challenges in making LDCT screening chest scans standard of care for high risk patients
It has been a couple of years since the National Lung Screening Trial demonstrated a clear survival benefit for low dose CT (LDCT) screening of patients who have a high risk of lung cancer (with “high risk” defined as age 55-75 and a significant smoking history). While lung cancer screening is offered in programs at various centers around the US, it remains a controversial procedure that has not been approved by Medicare as a covered service. On Thursday, September 25th, 8PM ET/ 5PM PT, we’ll discuss the existing barriers in lung cancer… Read More
#LCSM Chat Topic 4/24: Cost vs. Value with Expensive Cancer Treatments
Our topic for the upcoming #LCSM tweet chat on Thursday, April 24 at 8 PM Eastern, 5 PM Pacific is the question of “cost vs value” in cancer treatments. The moderator for this chat will be Dr. Jack West. ASCO (American Society of Clinical Oncology) has recently announced an initiative to define value in cancer treatments and apply some expectations of which drugs should be used, given their remarkable cost. Newer medications are typically costing about $10,000 per month, and the price is rising rapidly. Newer drugs have varying amounts of evidence… Read More
#LCSM 
You must be logged in to post a comment.